Evidence map›Paper›PMID 34648292›Full record

ArticleJournal of the American Chemical Society2021

Unraveling the Structural Basis of Selective Inhibition of Human Cytochrome P450 3A5.

Jingheng Wang, Cameron D Buchman, Jayaraman Seetharaman, Darcie J Miller, Andrew D Huber, Jing Wu, Sergio C Chai, Efren Garcia-Maldonado, William C Wright, Jude Chenge and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of the American Chemical Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Differential Effects of Clotrimazole on X-Ray Crystal Structures of Human Cytochromes P450 3A5 and 3A4.Drug metabolism and disposition: the biological fate of chemicals · 2023
    Article
  8. Pharmaceutical biology · 2022
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Jingheng WangDepartment of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, United States.
Cameron D BuchmanDepartment of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, United States.ORCID 0000-0003-2550-649X
Jayaraman SeetharamanDepartment of Structural Biology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, United States.
Darcie J MillerDepartment of Structural Biology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, United States.
Andrew D HuberDepartment of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, United States.
Jing WuDepartment of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, United States.
Sergio C ChaiDepartment of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, United States.ORCID 0000-0002-8257-8599
Efren Garcia-MaldonadoDepartment of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, United States.
William C WrightDepartment of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, United States.
Jude ChengeDepartment of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, United States.
Taosheng ChenDepartment of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, United States.ORCID 0000-0001-6420-3809
St. Jude Children's Research Hospital · US

Funding

X-ray Scattering Technology CoreP30GM133893 · NIGMS · BROOKHAVEN SCIENCE ASSOC-BROOKHAVEN LAB · PI Sean McSweeney · 2019 to 2026
$38.6M
Regulation of xenobiotic receptors PXR and CAR: implications in drug dispositionR35GM118041 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Taosheng Chen · 2016 to 2026
$4.3M
NIGMS NIH HHS P30 GM133893NIGMS NIH HHS R35 GM118041
6 · The paper itself

Abstract

The human cytochrome P450 (CYP) CYP3A4 and CYP3A5 enzymes metabolize more than one-half of marketed drugs. They share high structural and substrate similarity and are often studied together as CYP3A4/5. However, CYP3A5 preferentially metabolizes several clinically prescribed drugs, such as tacrolimus. Genetic polymorphism in

Indexed as

Anti-Inflammatory AgentsCatalytic DomainCytochrome P-450 CYP3ACytochrome P-450 CYP3A InhibitorsGene Expression Regulation, EnzymologicHumansModels, MolecularProtein ConformationStructure-Activity RelationshipAnti-Inflammatory AgentsCytochrome P-450 CYP3ACytochrome P-450 CYP3A Inhibitors

Identifiers

PMID34648292
PMCPMC8594567
OpenAlexW3207253128

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.